OARS funding Biomed

Objectives: The grant groundbreaking or unconventional methodologies, whose risky outlook is justified by the possibility of a major breakthrough. Basic Science: If a proposal is rooted in basic science, applicants are encouraged to collaborate with investigators who can further the potential for translation of ideas and findings. Translational Science: If a proposal is translational by nature, applicants are encouraged to identify industry and clinical partners to assist in propelling their research toward clinical study. Clinical Science: For those looking to submit a clinical research proposal, applicants are encouraged to collaborate with individuals who could facilitate potential clinical implementation.

The purpose of this Funding Opportunity Announcement (FOA) is to support milestone-driven projects focused on discovery, establishment of proof-of-concept for, and/or preclinical development of, lead candidate vaccines or immunoprophylactics that target multiple antimicrobial-resistant Gram-negative bacterial pathogens prevalent in nosocomial infections: carbapenem-resistant Enterobacteriaceae (CRE), multidrug-resistant (MDR) Acinetobacter and MDR Pseudomonas aeruginosa.

The NORD Research Grant Program provides seed-money grants to academic scientists for scientific and/or clinical research. The hope is that these studies will ultimately lead to new diagnostics, treatments, and/or cures for rare diseases. NORD's program provides grants for the study of diseases for which there are few other sources of funding. Grants provided through the NORD program are made possible by donations from individuals and organizations to restricted research funds at NORD.

The PCC has supported world-class research since 2008, spending more than $18.0 M to support novel science around the world. Research and grant-making are the foundation of the PCC and are the focus of everyday business activity. PCC-supported research contributes to a movement in addressing doping's root causes and ultimately decreasing the use of performance-enhancing drugs by all participants in all sports at all levels of play. Grant Cycle Deadlines: Pre-Applications are due March 1st, July 1st, and November 1st of each year. Applicants invited to submit full applications must do so by April 1st, August 1st, or December 1st, depending on the cycle (30 days after the pre-application due date). With an emphasis on original work that focuses on improving existing analytical methods for detecting particular drugs, developing new analytical methods to test for substances not currently detectable, and discovering cost-effective approaches for testing widely abused substances across all levels of sport, the following areas of investigation reflect the PCC's current research priorities: Developing methods of cost-effective testing to detect and deter the use of banned and illegal substances. Developing testing protocols to detect designer substances used for doping purposes. Improving existing analytical methods to detect particular drugs, ex. GH, IGF-1, EPO, hCG. Developing analytical methods to detect performance enhancing drugs not currently detectable. Longitudinal urinary excretion patterns, metabolism and dose-concentration. Critical reviews to support interpretation of laboratory data. Alternative specimens, (ex. oral fluid, dried blood/plasma spots) for testing. There is no maximum amount for PCC funding, though the average funding amount is $225,000. To date, over 80 projects have been funded in over 14 countries world-wide. Approximately 33% of applicants are awarded PCC funding.

The purpose of this Funding Opportunity Announcement (FOA) is to support milestone-driven projects focused on discovery, establishment of proof-of-concept for, and/or preclinical development of, lead candidate vaccines or immunoprophylactics that target multiple antimicrobial-resistant Gram-negative bacterial pathogens prevalent in nosocomial infections: carbapenem-resistant Enterobacteriaceae (CRE), multidrug-resistant (MDR) Acinetobacter and MDR Pseudomonas aeruginosa.

Applications to the Fiscal Year 2017 (FY17) Duchenne Muscular Dystrophy Research Program (DMDRP) are being solicited for the Defense Health Agency (DHA) J9, Research and Development Directorate, by the U.S. Army Medical Research Acquisition Activity (USAMRAA) using delegated authority provided by United States Code, Title 10, Section 2358 (10 USC 2358). As directed by the Office of the Assistant Secretary of Defense for Health Affairs (OASD[HA]), the DHA manages the Defense Health Program (DHP) Research, Development, Test, and Evaluation (RDT&E) appropriation. The execution management agent for this Program Announcement is the Congressionally Directed Medical Research Programs (CDMRP). The DMDRP was initiated in 2011 to provide support for research of exceptional scientific merit and to promote the understanding, diagnosis, and treatment of Duchenne. Appropriations for the DMDRP from FY11 through FY16 totaled $20 million (M). The FY17 appropriation is $3.2M.

The DMDRP Career Development Award mechanism supports early-career investigators in conducting impactful Duchenne research under the mentorship of an experienced muscular dystrophy researcher as an opportunity to obtain the funding, mentoring, and experience necessary for productive, independent careers at the forefront of Duchenne research. Applicants should also demonstrate that the proposed research has high potential to lead to or make breakthroughs in Duchenne. Preliminary data are required.

Enhance the investigations and prosecutions following large seizures of wildlife goods by building the capacity of law enforcement to process large seizures of wildlife products and to use the information derived from DNA mapping analysis of large seizures to augment investigations.

Applications to the Fiscal Year 2017 (FY17) Peer Reviewed Medical Research Program (PRMRP) are being solicited for the Defense Health Agency (DHA) J9, Research and Development Directorate, by the U.S. Army Medical Research Acquisition Activity (USAMRAA) using delegated authority provided by United States Code, Title 10, Section 2358 (10 USC 2358). As directed by the Office of the Assistant Secretary of Defense for Health Affairs (OASD[HA]), the DHA manages the Defense Health Program (DHP) Research, Development, Test, and Evaluation (RDT&E) appropriation. The execution management agent for this Program Announcement is the Congressionally Directed Medical Research Programs (CDMRP). The PRMRP was initiated in 1999 to provide support for military health-related research of exceptional scientific merit. Appropriations for the PRMRP from FY99 through FY16 totaled $1.371 billion. The FY17 appropriation is $300 million (M).

NineSigma, representing Novo Nordisk, seeks information on new or emerging technologies for delivery of protein and peptide based therapeutics, or on novel therapeutic approaches such as electroceutical technologies and bio-printing. Novo Nordisk is traveling to San Diego and San Francisco to hear in-person presentations from start-up companies or research groups in the San Diego area from June 9 - June 12, 2017 and San Francisco June 13 - June 15, 2017.

The purpose of this Funding Opportunity Announcement (FOA) is to continue development and expansion of the NIDDK Information Network (dkNET) under the direction of the dkNET Coordinating Unit (dkNET-CU). dkNET supports NIDDK research by providing a user-friendly web portal that seamlessly connects the NIDDK research community to an expanding universe of biomedical resources and data. The dkNET-CU will be responsible for providing the scientific direction, vision, and administrative management needed to advance dkNET goals.

This TRI RFA is soliciting applications for its Postdoctoral Fellowship Program. Postdoctoral Fellowships will be competitively awarded in any laboratory in the U.S. conducting biomedical/biotechnological research aligned with TRI's mission and goals (Section A). Applications will be screened for compliance and undergo a scientific/technical peer-review by an external peer-review committee consisting of a number of eminent scientists that are familiar with space biomedical/biotechnological research. Relevance to TRI's and NASA's programmatic needs and goals will also be evaluated by TRI management. Selections will be performed by the TRI Selection Official. The award is for two years of funding with an optional, competitively awarded third year of funding that may be available depending on existing TRI resources. Requests for a third year of funding will take into account the awardee's performance during the first two years of funding and be evaluated via external peer-review and also by TRI's Executive Council (TRIEC). All researchers, regardless of support by NASA or TRI, can serve as Mentors for this competitive funding.

Applications to the Fiscal Year 2017 (FY17) Peer Reviewed Medical Research Program (PRMRP) are being solicited for the Defense Health Agency (DHA) J9, Research and Development Directorate, by the U.S. Army Medical Research Acquisition Activity (USAMRAA) using delegated authority provided by United States Code, Title 10, Section 2358 (10 USC 2358). As directed by the Office of the Assistant Secretary of Defense for Health Affairs (OASD[HA]), the DHA manages the Defense Health Program (DHP) Research, Development, Test, and Evaluation (RDT&E) appropriation. The execution management agent for this Program Announcement is the Congressionally Directed Medical Research Programs (CDMRP). The PRMRP was initiated in 1999 to provide support for military health-related research of exceptional scientific merit. Appropriations for the PRMRP from FY99 through FY16 totaled $1.371 billion. The FY17 appropriation is $300 million (M).

This Funding Opportunity Announcement (FOA) encourages applications that propose to conduct secondary analyses of publicly available NICHD-funded data sets or stored biospecimens. The goal of this program is to facilitate innovative yet cost-effective research utilizing data and biospecimens collected with NICHD resources.  

 This award is intended to provide support to conduct clinical studies at a clinical site with capability and patients samples to investigate potential biomarker (cMLC1) for trastuzumab-induced cardiotoxicity. 1) There will be an establishment of the assay to quantitatively measure cMLC-1 in humans.  2) Investigations will be conducted to determine the value of cMLC-1 in humans as an early predictor of cardiotoxicity in a pilot study. A comparison will be done of the level of cMLC-1 in 5 patients who subsequently developed cardiotoxicity and 5 patients who did not. Patients will be matched for age. Cardiotoxicity was defined using the Cardiac Review and Evaluation Committee for Trastuzumab (CREC) criteria as a decrease of more than 10% in the echocardiographic left ventricular ejection fraction to a value of less than 55%. 3) Women were monitored every 3 months for 15 months. 4) The archived plasma samples collected at multiple time points indicated below schematically will be tested for the biomarker cMLC-1 and for troponin I, an established marker for heart muscle damage as a control.  

1) Policy/Advocacy: This category recognizes individuals who have demonstrated outstanding effort and leadership in policy/advocacy-related activities that improve the welfare of people living with or affected by HIV/AIDS, and/or whose work improves the delivery of prevention services to individuals and communities affected by HIV/AIDS. 2) Research: This category recognizes individuals who have demonstrated outstanding effort and leadership in the conduct, dissemination, and translation of high-quality research in the areas of HIV/AIDS prevention, treatment/care, and/or policy. 3) Service Provision: This category recognizes individuals who have demonstrated outstanding effort and leadership in the delivery of psychological services to people living with or affected by HIV/AIDS, and/or the delivery of technical or support services to community agencies that provide a range of HIV/AIDS-related services to individuals and communities affected by HIV/AIDS. 4) Teaching/Mentoring: This category recognizes individuals who have demonstrated outstanding effort and leadership in educating psychologists or students in psychology about HIV/AIDS practice, research, and/or policy. 

The Meso Foundation's research grant program offers grants for two years up to $50,000 per year. Eligible projects may relate to benchwork, translational or clinical research that is not presently funded and may be conducted through any not-for-profit academic, medical or research institution. We encourage all levels and degrees of scientists to apply.

The "3-D Retina Organoid'' Challenge (the "Challenge''), is an ideation Challenge in which the National Eye Institute (NEI; http://www.nei.nih.gov/), part of the National Institutes of Health (http://www.nih.gov(link is external)), is asking for ideas to maximize the physiological relevance of 3-D human retina culture systems. Currently, retina culture models do not capture the complexity of the human retina. The goal of the Challenge is to transform innovative ideas into concrete concepts to develop new in vitro 3-D human retina models that recapitulate the organization and function of the human retina. NEI intends to follow this challenge with a follow-on but distinct Reduction to Practice Challenge, which will aim to invoke scientific and technological development of the model system. Technological breakthroughs in this arena could allow researchers and physicians to better understand, diagnose, and treat retinal diseases.

This Funding Opportunity Announcement (FOA) encourages Research Project Grant (R01) applications to study molecular and cellular mechanisms of tissue injury and repair associated with alcohol use in humans. Excessive alcohol consumption has the potential to adversely affect multiple organ systems including the liver, brain, heart, pancreas, lung, kidney, endocrine and immune systems, as well as bone and skeletal muscle. In addition, there is accumulating evidence that long term alcohol consumption is associated with reduced host capacity for recovery and repair following trauma. The mechanisms for these alcohol-induced effects on tissue injury and repair are currently not fully understood.